论文部分内容阅读
[目的]探讨超分割放疗加同期化疗治疗Ⅲb期宫颈癌的应用价值。[方法]45例Ⅲb期宫颈癌前瞻性随机分两组,对比超分割放射治疗加同期化疗组(超分割组)和常规分割放射治疗加同期化疗组(常规分割组)疗效和副反应;影响超分割放疗加同期化疗疗效的单因素和多因素分析。[结果]除皮肤反应超分割组重于常规分割组外(P﹤0.01)外其他副反应差异无显统计学意义(P﹥0.05);放射反应率超分割组100%优于常规分割组76.19%(P﹤0.05);2年累计生存率超分割组92%与常规分割组55%比较差异无统计学意义。单因素和多因素分析表明肿瘤对外照射的反应是影响预后的唯一因素(P﹤0.01)。[结论]超分割放疗不加重放射副反应,在生存率有高于常规放疗的趋势,超分割放疗可作为宫颈癌放疗方法之一。
[Objective] To investigate the value of hyperfraction radiotherapy plus concurrent chemotherapy in the treatment of stage Ⅲb cervical cancer. [Method] Forty-five patients with stage Ⅲb cervical cancer were prospectively randomized to two groups. The effects and side effects of hyperfractionated radiotherapy plus concurrent chemotherapy (conventional radiofrequency ablation) versus conventional radiotherapy plus concurrent chemotherapy (conventional radiotherapy) were compared. Univariate and multivariate analysis of the effects of hyperfraction radiotherapy plus concurrent chemotherapy. [Results] There was no significant difference in any side effects except skin hyperfractionation group (P <0.01), and 100% of radiofrequency response superfractionation group was superior to 76.19 % (P <0.05). There was no significant difference between 92% of 2-year cumulative survival rate and 55% of conventional group. Univariate and multivariate analysis showed that tumor response to external radiation was the only factor affecting prognosis (P <0.01). [Conclusion] The hyperfraction radiotherapy does not aggravate the side effects of radiation. The survival rate is higher than that of conventional radiotherapy. Hyperfraction radiotherapy may be one of the radiotherapy methods for cervical cancer.